Evidence map›Paper›PMID 41924395›Full record

ArticleCanada communicable disease report = Releve des maladies transmissibles au Canada2026

Invasive pneumococcal disease surveillance in Canada, 2023.

Alyssa Golden, Averil Griffith, Brigitte Lefebvre, Allison McGeer, Gregory Tyrrell, Julianne Kus, Jennifer Grant, Jessica Minion, Paul Van Caeseele, Guillaume Desnoyers and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Canada communicable disease report = Releve des maladies transmissibles au Canada, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Alyssa GoldenNational Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB.
Averil GriffithNational Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB.
Brigitte LefebvreLaboratoire de santé publique du Québec, Institut national de santé publique du Québec, Sainte-Anne-de- Bellevue, QC.
Allison McGeerToronto Invasive Bacterial Diseases Network (TIBDN), Department of Microbiology, Mount Sinai Hospital, Toronto, ON.
Gregory TyrrellProvincial Laboratory for Public Health, Edmonton, AB.
Julianne KusPublic Health Ontario, Toronto, ON.
Jennifer GrantBritish Columbia Centre for Disease Control, Vancouver, BC.
Jessica MinionRoy Romanow Provincial Laboratory, Regina, SK.
Paul Van CaeseeleCadham Provincial Laboratory, Winnipeg, MB.
Guillaume DesnoyersLaboratoire de santé publique du New Brunswick, Moncton, NB.
David HaldaneQueen Elizabeth II Health Science Centre, Halifax, NS.
Yang YuNewfoundland and Labrador Public Health Laboratory, St. John's, NL.
Xiaofeng DingQueen Elizabeth Hospital, Charlottetown, PE.
Laura StevenStanton Territorial Hospital, Yellowknife, NT.
Jan McFadzenYukon Communicable Disease Control, Whitehorse, YK.
George ZhanelDepartment of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB.
Courtney PrimeauCentre for Emerging and Respiratory Infections and Pandemic Preparedness, Public Health Agency of Canada, Ottawa, ON.
Irene MartinNational Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Invasive pneumococcal disease (IPD), which is caused by Methods: The Public Health Agency of Canada's National Microbiology Laboratory (Winnipeg, Manitoba) collaborates with provincial and territorial public health laboratories to conduct national surveillance of IPD. Serotypes and minimum inhibitory concentrations were obtained from whole genome sequencing data. Results: The incidence of IPD in Canada was 10.2 cases per 100,000 population in 2022, increasing from the low rate of 5.6 cases per 100,000 population in 2021. A total of 4,760 IPD isolates were collected during 2023. The most common serotypes overall were 3 (12.3%, n=587), 4 (12.2%, n=580), 22F (8.2%, n=391) and 9V (7.1%, n=340). Serotypes 4 (7.1%-12.2%, Conclusion: The high number of IPD cases collected in 2023 represents a return to pre-SARS-CoV-2 pandemic disease activity. Several serotypes included in previous conjugate vaccine formulations are highly common or are increased in prevalence, including 3, 4 and 9V. Continued surveillance of pneumococcal serotypes is imperative to evaluate vaccine effectiveness, particularly as new vaccine formulations are approved and integrated into immunization schedules in Canada.

Indexed as

antimicrobial resistanceCanadaIPDPCV15PCV20pneumococcusserotypeStreptococcus pneumoniaesurveillanceV116

Identifiers

PMID41924395
PMCPMC13038169

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.